Check out your Company Bowl for anonymous work chats.
Our CEO Pascal Soriot shares our strong 2024 performance with continued double-digit growth and scientific progress across all Therapy Areas. We're also pleased to announce that AstraZeneca’s total annual dividend has increased by 7% to $3.10 per share and will further increase in 2025. This momentum reflects the great work of our teams to deliver for people, society and the planet. #WhatScienceCanDo
This year we are excited to celebrate our 25th anniversary with our teams around the world! We are pleased to report 2023 was another year of double-digit growth and scientific progress, with investments in exciting areas of science that lay the foundations for continued long-term success. We are committed to unlocking the power of what science can do for people, society and the planet.
Are you a final year MD/PhD student or Postdoctoral Researcher with an innovative R&D research idea? Submitting a proposal today has the potential to springboard careers whilst making a meaningful difference to patients and science.
Congratulations to our colleagues on their recognition as 2023 Healthcare Businesswomen’s Association “Luminaries” for their important work to advance women’s careers and their significant impact to the healthcare industry.
We are creating a culture of inclusion within our organization. Embracing the differences that make each of us unique so everyone can thrive.
Our purpose is simple: push the boundaries of science to deliver life-changing medicines. Our US business showcases the best of AstraZeneca with a combination of cutting-edge R&D and high-performance operations. Join an environment where you can thrive professionally and be inspired personally.
Our ambition is to create an inclusive and equitable environment where we all feel valued for the difference we bring. We’re on a journey and while we have made significant progress, we know there is more we can do to accelerate change for our employees, patients and the communities we serve.
AstraZeneca CEO Pascal Soriot speaks with Julia Chatterley of First Move (CNN) regarding the latest developments in the research and development of a COVID-19 vaccine.
A #COVID19 vaccine is crucial to helping us overcome this global pandemic. That is why we are partnering with the University of Oxford to support the global development, manufacturing and distribution of the University’s vaccine candidate if it proves to be effective.
In response to #COVID19, teams across AstraZeneca have moved quickly to maintain continuity of care, contribute to society, and use our scientific expertise to fight the pandemic. https://bit.ly/3f5gNO6
